Horizon Pharma Inc. (NASDAQ:HZNP)‘s stock had its “outperform” rating reiterated by analysts at BMO Capital Markets in a report released on Tuesday. They presently have a $30.00 price objective on the biopharmaceutical company’s stock. BMO Capital Markets’ target price suggests a potential upside of 56.58% from the stock’s current price.
HZNP has been the topic of several other research reports. Morgan Stanley set a $24.00 price target on shares of Horizon Pharma and gave the company a “hold” rating in a research report on Monday. Vetr raised shares of Horizon Pharma from a “buy” rating to a “strong-buy” rating and set a $21.00 price target on the stock in a research report on Monday, June 13th. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $33.00 price target (down previously from $34.00) on shares of Horizon Pharma in a research report on Wednesday, August 10th. Citigroup Inc. raised their price target on shares of Horizon Pharma from $18.00 to $21.00 and gave the company a “neutral” rating in a research report on Tuesday, August 9th. Finally, Goldman Sachs Group Inc. reaffirmed a “buy” rating and issued a $27.00 price target on shares of Horizon Pharma in a research report on Thursday, September 8th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $30.00.
Horizon Pharma (NASDAQ:HZNP) traded up 1.43% during trading on Tuesday, hitting $19.16. The stock had a trading volume of 5,546,138 shares. Horizon Pharma has a 1-year low of $12.86 and a 1-year high of $32.34. The firm’s market capitalization is $3.08 billion. The firm has a 50 day moving average price of $20.21 and a 200-day moving average price of $17.50.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/13/horizon-pharma-inc-hznp-receives-outperform-rating-from-bmo-capital-markets.html
Horizon Pharma (NASDAQ:HZNP) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.12. The company earned $257.40 million during the quarter, compared to the consensus estimate of $235.43 million. Horizon Pharma had a positive return on equity of 23.46% and a negative net margin of 0.34%. The firm’s revenue for the quarter was up 48.9% compared to the same quarter last year. During the same period last year, the business posted $0.39 EPS. On average, equities research analysts expect that Horizon Pharma will post $2.15 EPS for the current year.
In related news, EVP Jeffrey W. Sherman sold 2,900 shares of Horizon Pharma stock in a transaction that occurred on Tuesday, August 2nd. The shares were sold at an average price of $20.00, for a total value of $58,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Virinder Nohria sold 25,000 shares of Horizon Pharma stock in a transaction that occurred on Wednesday, June 15th. The shares were sold at an average price of $17.69, for a total transaction of $442,250.00. Following the completion of the transaction, the director now owns 189,836 shares of the company’s stock, valued at $3,358,198.84. The disclosure for this sale can be found here. 2.10% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HZNP. BlackRock Fund Advisors raised its position in Horizon Pharma by 127.3% in the second quarter. BlackRock Fund Advisors now owns 6,678,136 shares of the biopharmaceutical company’s stock worth $109,989,000 after buying an additional 3,740,449 shares in the last quarter. State Street Corp raised its position in Horizon Pharma by 149.1% in the second quarter. State Street Corp now owns 4,201,164 shares of the biopharmaceutical company’s stock worth $69,194,000 after buying an additional 2,514,430 shares in the last quarter. Deerfield Management Co. raised its position in Horizon Pharma by 17.6% in the first quarter. Deerfield Management Co. now owns 13,740,261 shares of the biopharmaceutical company’s stock worth $227,676,000 after buying an additional 2,055,460 shares in the last quarter. Fiera Capital Corp acquired a new position in Horizon Pharma during the second quarter worth $28,892,000. Finally, Norges Bank acquired a new position in Horizon Pharma during the fourth quarter worth $29,651,000. Institutional investors and hedge funds own 85.25% of the company’s stock.
About Horizon Pharma
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.
Receive News & Ratings for Horizon Pharma Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Horizon Pharma Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.